Related Experiment Video
Updated: Sep 6, 2025
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
CYLD expression in endometrial carcinoma and correlation with clinicohistopathological parameters
Vasiliki Papadatou1, Stylianos Tologkos1, Avgi Tsolou1
1Laboratory of Histology-Embryology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Objective:
Endometrial cancer is a threat to women health worldwide. Cylindromatosis (CYLD) enzyme is a tumour suppressor, considered an effective prognostic marker in various malignancies, but its role in endometrial carcinoma is not fully elucidated. Here, we sought to estimate the prognostic value of CYLD expression in endometrial carcinoma.
Materials And Methods:
CYLD levels were immunohistochemically evaluated in 65 patients with endometrial carcinoma and inferential statistics were applied.
Results:
Low or negative CYLD expression significantly correlates with older ages, non-endometrioid and invasive carcinomas, tumours with moderate or poor differentiation and advanced stages. Moreover, non-endometrioid and invasive carcinomas are independent risk factors for weaker CYLD expression. Kaplan-Meier analysis illustrated that negative or low CYLD expression is statistically significantly associated with increased death risk, compared to moderate or high expression.
Conclusion:
This study demonstrates for the first time a clear correlation between CYLD expression and clinicohistopathological parameters of endometrial carcinoma patients, suggesting its use as a potential prognostic/predictive marker for Endometrial Carcinoma.
